Is TB-500 Legal in Kentucky? What Federal Rules Say

HealthRX.com

No general federal route to compound TB-500 exists

Print or save as PDF

See the public record for TB-500

  • What it is / A synthetic 7-amino-acid fragment of thymosin beta-4, not the full protein [1]
  • FDA approval / None in the US or in the countries FDA reviewed [1]
  • FDA compounding lists / On neither the pharmacy bulks list nor the outsourcing-facility list [2][3][4]
  • Advisory committee / Voted for listing on July 23, 2026; advice only [7][5]
  • HHS policy / Proposed conditional enforcement discretion for TB-500 acetate injections [5][6]
  • Sport / Prohibited at all times by WADA [8][9]

Is TB-500 approved in the US?

No. FDA's July 2026 review found no USP or National Formulary monograph for it, no FDA-approved drug containing it, and no approved product in the other countries it reviewed or authorized by the European Medicines Agency [1].

TB-500 is a common name, not an official drug name. It is a synthetic 7-amino-acid, N-acetylated fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, about 889 g/mol, and FDA found several salts and derivatives sold under that name [1].

What decides whether a pharmacy can make it?

Under federal compounding rules, a state-licensed pharmacy may use a bulk substance only if a USP or National Formulary monograph exists, it is a component of an FDA-approved drug, or it appears on FDA's bulks list [4]. TB-500 meets none of those conditions: it appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or on FDA's list for outsourcing facilities (updated March 21, 2025), and the category 1 policy does not cover it [2][3][4].

It does sit in the nominated-but-withdrawn table on FDA's safety-risk page, which holds substances previously in category 2 whose nominators withdrew them; removal from category 2 was not a finding that TB-500 is safe [10].

What has changed in 2026?

FDA staff proposed in a July 2026 briefing document that neither TB-500 free base nor TB-500 acetate be added to the pharmacy bulks list, citing no human data and immunogenicity risk from injection [1]. The Pharmacy Compounding Advisory Committee reviewed TB-500 on July 23, 2026 and voted in favor of adding it, against staff's recommendation; the vote is advice only, and adding a substance takes formal rulemaking [7][5].

HHS then filed a draft enforcement-discretion policy on October 28, 2026 naming TB-500 among six peptides. It covers TB-500 acetate injected subcutaneously or intramuscularly and says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it when the policy's conditions are met. Examples of those conditions are a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and the label 'This is a compounded drug product. Not for resale.' The notice states it 'does not establish any rights for any person and is not binding on HHS or the public'; it is not an approval, and HHS may revisit it, for example if a safety signal or product quality issue arises [5][6].

What about Kentucky?

The federal restrictions above apply in Kentucky. HHS has proposed limited enforcement discretion for TB-500 acetate injections prepared under specified conditions, including a patient-specific prescription. The proposal does not approve TB-500 or establish a general legal way to obtain it in Kentucky [5][6]. This page does not address whether Kentucky law adds requirements.

What else should a patient know?

There is no approved dose and no human dosing study of TB-500 [1]. It is sold online as research-use-only injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1]. WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times in and out of competition [8][9]. FDA's adverse-event database search through March 26, 2025 retrieved no TB-500 reports, and it found no published case reports, so safety in humans is unknown; its stated concern for injectable TB-500 is immunogenicity, potentially amplified by peptide aggregation and impurities [1].

Questions worth asking

Choose the questions you want to keep

Is TB-500 legal in Kentucky?
TB-500 is not an FDA-approved drug and is on none of FDA's compounding lists, so federal rules give no general legal route to compound it [1][2][3][4]. HHS's draft policy would provide only conditional enforcement discretion for certain TB-500 acetate injections; it would not make TB-500 approved or automatically legal [5][6]. Kentucky-specific rules are not covered here.
Did the 2026 advisory vote make TB-500 legal?
No. The Pharmacy Compounding Advisory Committee voted in favor of adding it to the bulks list on July 23, 2026, against FDA staff's recommendation. The vote is non-binding and adding a substance takes formal rulemaking [7][5].
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic 7-amino-acid, N-acetylated fragment (residues 17 to 23) of the 43-amino-acid protein thymosin beta-4, and studies of the full protein do not show that the fragment works or is safe [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Does TB500 show up on a drug test?

Standard drug tests are not addressed in the available information. What is established is that WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, prohibited at all times, in and out of competition.

Is BPC-157 and TB-500 sold in the same vial legit?

TB-500 is sold online as research-use-only injectable powder, both alone and blended with BPC-157. Whether such blends are legitimate is not established. The proposed HHS policy lists a single active ingredient among its conditions, so a blend would not meet them, and the policy is not an approval.

Show all 10 referencesHide references
Evidence overview for Is TB-500 Legal in Kentucky? What Federal Rules Say